Pacific Marine Biotech (PMB) is a United States-based biotech company founded in December 2021 by Samuel Grant and Alan Temkin. Our team’s mission is to provide a safe and natural treatment solution for DIPG and Glioblastoma that restores Quality of Life by securing FDA orphan drug approval for Immune12.
PMB’s immediate objective is to create partnerships with leading healthcare institutions in the United States for the purpose of conducting clinical trials on Immune12. We envision a future in which we can positively change the way cancer is treated, rewriting the narrative for thousands of cancer patients every year and for the betterment of communities around the world.